Safety Panic: Tysabri, Byetta and the Challenge of Risk Communication on Wall Street
This article was originally published in RPM Report
There is no question someone is over-reacting to safety issues with Biogen Idec/Elan's Tysabri and Lilly/Amylin's Byetta. But is it FDA-or investors?
You may also be interested in...
FDA Risk Communication Strategy May Include Overhaul Of Labeling Language
As FDA assesses its new risk management powers and overall drug safety strategy, it continues to focus on how to revise what has been its primary communications tool for decades - product labeling
Next Chapter In The Amylin Chronicles: Job Cuts, Restructuring
Troubled by slower Byetta growth and uncertainty around the development of a long-acting version, Amylin will cut 25 percent of its San Diego workforce.
Amylin Speculation Intensifies: Byetta LAR May Be Delayed
Comparability studies could mean filing is impossible for first half of 2009, Amylin says.